Skip to main content
CSUI logo

Cannabis Suisse Corp. (CSUI) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.0078 -$0.0001 (-1.27%)
P/E Ratio: 4.65| Vol: 3.8K| 52-wk range: $0.0028 – $0.023

P/E 4.65 means the share price is 4.65 times one year of earnings per share.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Cannabis Suisse Corp. (CSUI) trades at $0.0078. Cannabis Suisse Corp. operates in the healthcare sector, focusing on the production and distribution of over-the-counter products, recreational tobacco, and medical CBD oils. Sector: Real estate.

Price as of · Last analyzed: Mar 16, 2026
Cannabis Suisse Corp. operates in the healthcare sector, focusing on the production and distribution of over-the-counter products, recreational tobacco, and medical CBD oils. The company utilizes its Swiss4Life brand and a network of retailers to reach consumers.

Analyst Coverage for CSUI: CSUI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

▶ Watch the CSUI film Every key number, told as a short cinematic story — just press play. ~2 min

No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.

Cannabis Suisse Corp. (CSUI) Real Estate Portfolio & Strategy

CEOScott W. Mcalister
HeadquartersJacksonville, US
IPO Year2019

Cannabis Suisse Corp. is a healthcare company focused on over-the-counter products, recreational tobacco, and medical CBD oils, distributed through its Swiss4Life brand and a retail network. With a high profit margin but negative gross margin, the company operates in a competitive and evolving market landscape.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 16, 2026

What Is the Investment Thesis for CSUI?

AI-written as of Mar 16, 2026 — figures and tone reflect the data available then, not today's score.

Cannabis Suisse Corp. presents a complex investment profile. While the company boasts a high profit margin of 1469.1%, its negative gross margin of -54.7% raises concerns about operational efficiency and cost management. The company's focus on over-the-counter products, recreational tobacco, and medical CBD oils positions it in a market with both growth potential and regulatory uncertainty. Key value drivers include the expansion of its Swiss4Life brand and the establishment of strategic retail partnerships. Upcoming regulatory changes in the cannabis industry could significantly impact the company's operations and profitability. Investors should closely monitor the company's ability to improve its gross margin and navigate the evolving regulatory landscape.

Based on FMP financials and quantitative analysis

CSUI Key Highlights

AI-written as of Mar 16, 2026 — figures and tone reflect the data available then, not today's score.

Profit Margin of 1469.1% indicates high profitability, but needs further investigation into the drivers and sustainability.

  • Negative Gross Margin of -54.7% signals potential issues with cost of goods sold and pricing strategies.
  • Market Cap of $0.00B indicates the company is a micro-cap stock with high volatility and risk.
  • P/E Ratio of 4.65 suggests the stock may be undervalued compared to its earnings, but should be considered alongside other financial metrics.
  • Beta of -4.65 indicates the stock is negatively correlated with the market, which may offer diversification benefits but also reflects unique company-specific risks.

Who Are CSUI's Competitors?

CSUI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
NGMC Next Generation Management Corp. $1.03 0.00% —
LRHC La Rosa Holdings Corp. $1.56 -15.22% —
UK Ucommune International Ltd $1.95 -3.44% —
AIRE reAlpha Tech Corp. $1.32 +0.76% $7.08M —
FTHM Fathom Holdings Inc. $0.23 -32.27% $7.52M —
GYRO Gyrodyne, LLC $4.56 -2.85% $10.0M —
WETH WETH $0.99 -0.70% $11.9M —
OPAD Offerpad Solutions Inc. $3.08 -5.38% $14.9M —

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CSUI's Key Strengths?

Established Swiss4Life online retail brand.

  • Diversified product line including cannabis-related and health-related products.
  • Early mover advantage in the emerging cannabis market.
  • High reported profit margin (though offset by negative gross margin).

What Are CSUI's Weaknesses?

Negative gross margin indicates potential issues with cost management.

  • Limited market capitalization and potential liquidity concerns.
  • Reliance on a relatively new and evolving regulatory landscape.
  • Limited brand recognition compared to larger competitors.

What Are the Key Risks for CSUI?

Financial-distress signal — its Altman Z-Score of -12.62 sits in the distress zone (elevated bankruptcy risk).

  • Negative return on equity (-6.1%) — the business is not currently generating profit on shareholder capital.
  • Intense competition from established pharmaceutical companies and emerging cannabis businesses.
  • Evolving regulatory landscape and potential changes in cannabis laws.
  • Fluctuations in commodity prices and supply chain disruptions.
  • Negative public perception and potential health concerns related to cannabis and tobacco products.
  • Negative gross margin indicating potential issues with cost management.

What Are CSUI's Competitive Advantages?

  • Established Swiss4Life online retail brand.
  • Network of retail distribution partners.
  • Diversified product line including cannabis-related and health-related products.
  • Early mover advantage in the emerging cannabis market.

What Does CSUI Do?

Cannabis Suisse Corp., formerly Geant Corp., was established in 2016 and rebranded in February 2019 to reflect its focus on cannabis-related products. Headquartered in Bell Gardens, California, the company cultivates, produces, and distributes a range of products including over-the-counter health supplements, recreational tobacco products, and medical CBD oils. Its primary retail channel is Swiss4Life, an online brand, supplemented by a network of retailers. The product line extends beyond cannabis-related items to include health-related supplements, face masks, disinfectants, and traditional cigarettes. This diversified approach aims to capture a broader market segment within the health and wellness sector. The company's strategy involves leveraging both direct-to-consumer online sales and established retail partnerships to enhance market penetration and brand visibility. Cannabis Suisse Corp. operates within the evolving regulatory landscape of the cannabis industry, adapting its business model to comply with local and international laws.

What Products and Services Does CSUI Offer?

  • Cultivates and produces over-the-counter products.
  • Manufactures and distributes recreational tobacco products.
  • Produces and sells medical CBD oils.
  • Sells products through the Swiss4Life online retail brand.
  • Distributes products through a network of retailers.
  • Offers health-related supplements.
  • Provides face masks and disinfectants.
  • Retails cigarettes.

How Does CSUI Make Money?

  • Cultivation and production of cannabis-related products.
  • Direct-to-consumer sales through the Swiss4Life online platform.
  • Distribution through a network of retail partners.
  • Sales of health-related supplements and other wellness products.

What Industry Does CSUI Operate In?

Cannabis Suisse Corp. operates within the specialty and generic drug manufacturing industry, a segment of the broader healthcare sector. The industry is characterized by intense competition, evolving regulatory landscapes, and increasing consumer demand for health and wellness products. Market trends include the growing acceptance of CBD products and the legalization of cannabis in various jurisdictions. Cannabis Suisse Corp. competes with established pharmaceutical companies and emerging cannabis businesses, navigating a complex environment of regulatory compliance and market differentiation. The company's success depends on its ability to innovate, adapt to changing regulations, and effectively market its products to a diverse consumer base.

Who Are CSUI's Key Customers?

  • Consumers seeking over-the-counter health and wellness products.
  • Individuals interested in recreational tobacco products.
  • Patients seeking medical CBD oils for therapeutic purposes.
  • Online shoppers through the Swiss4Life platform.
  • Retail customers through the company's network of retail partners.
Model self-rating on this text: 69% (not a measure of the evidence) Updated: Mar 16, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● No usable price
  • ● No filing on record
  • ● No analyst coverage

Company Profile

Cannabis Suisse Corp. operates in the Real Estate sector. It is headquartered in Jacksonville, US. The company is led by CEO Scott W. Mcalister. CSUI has traded publicly since 2019.

Insider Activity

2 transactions · 0 purchases, 0 sales, 2 other transactions · 1 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

F-Score 5/9

Financial Health

Cannabis Suisse Corp.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -12.62 places it in the distress zone, a signal of elevated financial risk.

ROE -6%

Key Financial Metrics

Return on equity for Cannabis Suisse Corp. stands at -6.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 23.6%, showing how much profit it generates from its asset base. CSUI trades at a trailing price-to-earnings ratio of 4.65, below the Healthcare sector average of ~21.10x. Its free cash flow yield is -9.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.27 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 16.7%, the inverse of the P/E and a quick read on earnings relative to price.

CSUI Financials

Fundamental Snapshot

Revenue Growth (FY)
-6.7%
Net Income Growth (FY)
+126.9%
EPS Growth (FY)
+126.2%
Free Cash Flow Growth (FY)
+10.6%
P/E (TTM)
4.65
Return on Equity (TTM)
-6.1%
Current Ratio
0.3

Based on FMP financials and quantitative analysis · FY 2026

CSUI Latest News

No recent news available for CSUI.

CSUI Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CSUI.

Price Targets

Wall Street price target analysis for CSUI.

CSUI MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CSUI; grades run from A+ (80-100) to F (below 30).

Leadership: Scott W. Mcalister

CEO

Information on Scott W. Further research would be needed to determine his career history, education, and previous roles.

Track Record: Information on Scott W. Mcalister's track record is not available in the provided context. Further research would be needed to determine his key achievements, strategic decisions, and company milestones under his leadership.

CSUI OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, indicating that Cannabis Suisse Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, and trading activity can be sporadic. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. Investors should exercise extreme caution and conduct thorough due diligence before investing in companies on this tier.

  • OTC Tier: OTC Other
Liquidity: Liquidity for Cannabis Suisse Corp. on the OTC market is likely limited, given its OTC Other status. This typically translates to low trading volume and a wider bid-ask spread, making it more difficult to buy or sell shares quickly and at a desired price. Investors may experience significant price fluctuations and potential delays in executing trades due to the limited number of market participants.
OTC Risk Factors:
  • Limited financial disclosure and transparency.
  • Potential for fraud and manipulation.
  • Low trading volume and liquidity.
  • Wider bid-ask spreads and price volatility.
  • Lack of regulatory oversight and investor protection.
Due Diligence Checklist:
  • Verify the company's legal status and registration.
  • Review available financial statements and disclosures.
  • Assess the company's business model and competitive landscape.
  • Evaluate the management team and their track record.
  • Understand the risks associated with the OTC market and the company's specific industry.
  • Consult with a financial advisor before making any investment decisions.
Legitimacy Signals:
  • Company's operational history since 2016.
  • Existence of a retail brand (Swiss4Life).
  • Engagement in cultivation, production, and distribution activities.
  • Physical headquarters in Bell Gardens, California.

Common Questions About CSUI (Real Estate)

What does Cannabis Suisse Corp. do?

Cannabis Suisse Corp. cultivates, produces, and distributes a range of products including over-the-counter health supplements, recreational tobacco products, and medical CBD oils. The company sells its products through its Swiss4Life online retail brand and a network of retail partners.

What do analysts say about CSUI stock?

There is currently no available analyst coverage for Cannabis Suisse Corp. (CSUI). Given its OTC listing and micro-cap status, the company may not be actively tracked by major brokerage firms.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

MoonshotScore is not published for this security.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Limited information available on CEO's background and track record.
  • OTC market stocks are inherently riskier than exchange-listed stocks.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis